In This Article:
As global markets exhibit mixed signals with the S&P 500 reaching new heights amidst a cooling labor market and falling interest rates, investors are keenly observing shifts in economic indicators that could impact investment decisions. In this context, undervalued small-cap stocks with insider buying present a compelling area for consideration, potentially offering resilience and growth opportunities against broader market volatility.
Top 10 Undervalued Small Caps With Insider Buying
Name | PE | PS | Discount to Fair Value | Value Rating |
---|---|---|---|---|
Dundee Precious Metals | 9.1x | 3.1x | 41.41% | ★★★★★★ |
AtriCure | NA | 2.7x | 47.85% | ★★★★★☆ |
Titan Machinery | 3.9x | 0.1x | 25.84% | ★★★★★☆ |
Columbus McKinnon | 21.2x | 1.0x | 48.19% | ★★★★☆☆ |
Norconsult | 28.0x | 1.0x | 43.68% | ★★★☆☆☆ |
Citizens & Northern | 12.4x | 2.8x | 39.17% | ★★★☆☆☆ |
Ramaco Resources | 13.9x | 1.1x | 12.03% | ★★★☆☆☆ |
Trifast | NA | 0.4x | -46.18% | ★★★☆☆☆ |
Community West Bancshares | 18.7x | 2.9x | 42.25% | ★★★☆☆☆ |
Delek US Holdings | NA | 0.1x | -134.46% | ★★★☆☆☆ |
Underneath we present a selection of stocks filtered out by our screen.
AddLife
Simply Wall St Value Rating: ★★★★★☆
Overview: AddLife is a company specializing in life science products and services, operating primarily in the Labtech and Medtech sectors with a market capitalization of approximately SEK 9.80 billion.
Operations: Labtech and Medtech are the primary revenue contributors, generating SEK 3.61 billion and SEK 6.20 billion respectively. The company's gross profit margin has shown a slight increase over recent periods, reaching approximately 37.17% by the end of the latest reported period in 2024.
PE: 218.4x
Recently, AddLife has shown a mixed financial landscape, with first-quarter sales rising to SEK 2.57 billion from SEK 2.46 billion year-over-year, yet net income dipped significantly to SEK 62 million from SEK 174 million. Despite this, insider confidence is evident as earnings are projected to surge by over 56% annually. This optimism is underscored by strategic decisions made during their latest board meeting and a modest dividend payout adjustment, reflecting a cautious yet forward-looking management approach in navigating current market challenges.
-
Navigate through the intricacies of AddLife with our comprehensive valuation report here.
-
Examine AddLife's past performance report to understand how it has performed in the past.
Vimian Group
Simply Wall St Value Rating: ★★★★★☆
Overview: Vimian Group is a diversified healthcare company, operating across multiple segments including Medtech, Diagnostics, Specialty Pharma, and Veterinary Services with a market capitalization of approximately €1.00 billion.